Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.
Actively Recruiting
Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.
Actively Recruiting
This research aims to evaluate a shorter, 1-week course of partial breast re-irradiation rPBI after breast-conserving surgery for women with recurrent or new primary breast cancer in a previously irradiated breast. The study focuses on women who have had prior whole breast radiation and now face local recurrence, assessing whether this ultra-hypofractionated radiation approach results in acceptable levels of toxicity at one year. This approach is thought to reduce side effects and improve cosmetic outcomes compared to traditional longer treatments or mastectomy. Participants receive external beam rPBI delivering 26 Gy in 5 daily fractions over one week following a second lumpectomy. This phase 2, single-arm, multi-institutional trial enrolls women with localized recurrence or new cancer in the previously irradiated breast. The treatment aims to be more convenient with fewer sessions while maintaining safety and effectiveness, advancing knowledge on optimal care for this patient group. During the study, participants will undergo regular assessments of radiation-associated toxicity, recurrence risk, survival, and quality of life at multiple time points up to five years post-treatment. Evaluations include physical exams, imaging, and questionnaires on breast satisfaction and financial impact. The primary outcome is grade 3 or higher toxicity during the three-year accrual period. This long-term monitoring ensures safety and gathers data on treatment effects over time.
Actively Recruiting
Researchers are evaluating treatments for participants with metastatic colorectal cancer who have a specific KRAS p.G12C mutation and have not received prior treatment. The study compares progression-free survival between two groups one receiving sotorasib, panitumumab, and FOLFIRI, and the other receiving FOLFIRI with or without bevacizumab-awwb. This is a phase 3 randomized trial aiming to understand which combination better manages the disease. Participants in one group take sotorasib daily as an oral tablet while receiving panitumumab and FOLFIRI every two weeks through intravenous infusions. The other group receives FOLFIRI every two weeks, with or without bevacizumab-awwb, also given by intravenous infusion every two weeks. The study treatments continue according to these schedules to compare their effects. Throughout the trial, participants will undergo assessments to measure progression-free survival using RECIST v1.1 criteria for up to approximately three years. Additional outcomes like overall survival, response rates, duration of response, and safety events are monitored for up to five years. Researchers will collect blood samples to measure sotorasib levels during early treatment cycles. Participants are closely observed through scheduled visits and tests to evaluate treatment effects and safety over the study duration.
Actively Recruiting
Non small cell lung carcinoma NSCLC is the most common type of lung cancer and a leading cause of cancer deaths worldwide. This research aims to evaluate adverse events and changes in disease activity when Telisotuzumab Adizutecan ABBV-400 is combined with a PD-1 immune checkpoint inhibitor in adults with advanced or metastatic non-squamous NSCLC who have not received prior treatment for advanced disease and have no actionable genomic alterations. The study is conducted in multiple phases to assess safety, efficacy, and optimal dosing. Participants are treated in two stages. The first stage involves escalating doses of intravenous Telisotuzumab Adizutecan combined with Budigalimab to find a tolerable and effective dose. In the second stage, participants are randomized into three groups two groups receive different optimized doses of Telisotuzumab Adizutecan combined with Pembrolizumab, and one group receives standard care, which includes Pembrolizumab, Pemetrexed, and either Carboplatin or Cisplatin, followed by Pembrolizumab and Pemetrexed. The total study duration is approximately 33 months. Participants attend regular visits at approved hospitals or clinics during the study. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect tracking. Researchers measure dose-limiting toxicities, objective response, progression-free survival, duration of response, disease control, overall survival, and subgroup responses based on PD-L1 and c-Met status. Safety and efficacy outcomes are observed for up to about 33 months.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how the use of an interactive projector-based video game as a distraction during anesthetic mask induction affects anxiety levels in children aged 2 to 6 years. The study focuses on perioperative anxiety measured by the Modified Yale Preoperative Anxiety Scale mYPAS and compares this technology intervention with standard care. It is a randomized, controlled, open-label clinical trial conducted in a Latin American setting. Participants are randomly assigned to one of two groups one receiving routine mask induction with a parent present and no additional distraction, and the other receiving the same parent-present induction along with the interactive video game projected in front of the child. The projection is designed to engage children from their arrival in the operating room throughout the induction process, and the intervention ends when the child loses consciousness and standard care resumes. During the study, researchers will observe and measure the childs anxiety, cooperation, compliance, and caregiver satisfaction during and after anesthetic induction. Additional assessments include behavioral outcomes two weeks after surgery and correlations with physiological measures at mask application. The study includes setup and operation of the projection system by research staff, and participants will be monitored throughout the perioperative period. Total participation includes the induction phase and follow-up assessments after surgery.